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Abstract
Background: Not all women infected with HPV-16/18 have detectable levels of HPV-16/18 antibodies, those who
seroconvert develop low antibody levels, and seroconversion occurs typically several months post-infection. We
evaluated determinants of seropositivity among 646 women infected with HPV-16 and/or HPV-18.
Methods: Data are from the enrollment visit of the NCI-sponsored Costa Rica HPV Vaccine Trial. Sera were tested
for HPV-16/18 antibodies by ELISA; cervical specimens were tested for HPV DNA using HC2 and SPF10/LiPA25. Odds
ratios (OR) and 95% confidence intervals (CI) were computed.
Results: Among HPV-16/18 DNA positives, seropositivity was 63.0% and 57.5%, respectively. Among HPV-16 DNA
positives, seropositivity increased with lifetime number of sexual partners (p-trend = 0.01). Women with abnormal
cytology and/or high viral load had a 1.63-2.79-fold increase in the detection of antibodies compared to women
with normal cytology/low viral load. Current users of oral contraceptives had a 1.88-fold (95%CI, 1.14-3.09)
increased detection of antibodies and current users of injectables had a 3.38-fold (95%CI, 1.39-8.23) increased
detection compared to never users. Among HPV-18 DNA positive women, seropositivity was associated with
current oral contraceptive use (OR 2.47; 95%CI 1.08-5.65).
Conclusions: Factors associated with sustained HPV exposure (abnormal cytology, elevated HPV viral load,
increasing lifetime partners) were predictive of HPV-16 seropositivity. Hormonal contraceptive use was associated
with seropositivity suggesting an effect of hormones on immune responses to HPV. Patterns were less consistent
for HPV-18. Follow up of incident HPV infections to evaluate seroconversion and their determinants is needed.
Background
Infections with most viruses typically result in rapid
generation of antibodies that protect against re-infec-
tion. In contrast, not all women infected with human
papillomavirus (HPV) 16/18 have detectable levels of
anti HPV-16/18 antibodies. Women who seroconvert
develop low antibody levels and seroconversion occurs
within months and varies among women [1,2]. The slow
and weak antibody response generated by HPV infec-
tions could be explained by its life-cycle in the host.
HPV is shed within intact cells lining mucosal surfaces,
which limits exposure of the host immune system to the
virus. HPV infected cells that undergo lysis (i.e. koilo-
cytes) are shed to the environment and infections do
not produce viremia. Finally, infections produce a lim-
ited load of HPV antigenic proteins [3,4].
Several studies have shown that, as expected, sexual
behavior is the strongest predictor of HPV-16/18 anti-
body detection [5-7]. Other factors identified less consis-
tently (smoking [8,9], oral contraceptive use [7], and
history of other sexual transmitted infections [10]) could
represent residual confounding by sexual behavior.
In contrast to studies that have evaluated the overall
determinants of HPV-16/18 seropositivity, which cannot
distinguish risk factors for exposure/infection from
those associated with seroconversion given infection,
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any medium, provided the original work is properly cited.little is known about the specific predictors of seroposi-
tivity given concomitant infection with cervical HPV-16
or HPV-18. To better understand why some women
with cervical HPV-16/18 infection have detectable levels
of antibodies while others do not, using data from a
community-based HPV-16/18 vaccine trial of 7,466
women aged 18-25 years in Costa Rica, we analyzed the
determinants of HPV-16 and18 seropositivity among the
subset of 646 women found to be infected with cervical
HPV-16 and/or HPV-18 at enrollment.
Methods
Study population
Data are from the enrollment (pre-vaccination) visit of a
trial investigating efficacy of an HPV-16/18 vaccine to
prevent infections and cervical neoplasia in the pro-
vinces of Guanacaste and Puntarenas, Costa Rica. The
study design and procedures have been described in
detail [11]. Briefly, women were identified through a
population census and women 18 to 25 years old were
invited to participate between June 2004-December
2005. A total of 7,466, approximately 60% of eligible
women (30.5% of the census), agreed to participate and
fulfilled the inclusion criteria. Eligible women were not
hysterectomized, pregnant or lactating, were mentally
competent, in good general health, willing to use a con-
traceptive method during the vaccination phase.
Women with a history of chronic or immunodeficiency
conditions or with a history of hepatitis A infection or
vaccination against it, were excluded.
Study procedures
At the clinic women gave informed consent and were
interviewed. Information regarding sociodemographic
factors, reproductive and sexual history, contraceptive
use, and smoking were obtained. A physician obtained
the medical history and performed a physical exam
including a pelvic exam among sexually experienced
women. At the pelvic exam, exfoliated cervical cells
were collected using a Cervex brush and were rinsed
into a vial containing 20 mL of PreservCyt solution.
Samples were transported to the laboratory, where two
0.5 ml aliquots were drawn for HPV DNA testing by
PCR. ThinPrep slides were prepared for cytology, and
the remaining solution was used for HPV DNA detec-
tion by Hybrid Capture 2 (HC2). A blood sample was
collected from all participants using a 10 ml vacutainer
tube without additive. At the local laboratory serum ali-
quots for the determination of HPV-16 and HPV-18
antibodies by ELISA were obtained and frozen
immediately.
Protocols were approved by the institutional review
boards of INCIENSA, Costa Rica and National Cancer
Institute, United States.
HPV DNA detection and genotyping by SPF10/DEIA/LiPA25
system
HPV DNA detection and genotyping was performed at
DDL Diagnostic Laboratory (DDL, Voorburg, The
Netherlands) using PCR amplification with SPF10 pri-
mers followed by DNA enzyme immunoassay detection
of amplimers. HPV typing on positive amplimers was
performed using line probe assay (LiPA25) (Labo Bio-
medical Products, Rijswijk, Netherlands), as previously
described [12].
Since the trial uses a bivalent HPV-16/18 vaccine to
maximize sensitivity for these types, all specimens that
tested positive by SPF10 DEIA but negative for HPV-16
or HPV-18 by LiPA25 were tested for the presence of
HPV-16 and HPV-18 using type-specific PCR primers
set, as previously described [13,14].
The results of this assay were used to identify the
group of women HPV-16 DNA positive or HPV-18
DNA positive at the enrollment visit of the vaccine trial.
HPV DNA detection by Hybrid Capture 2
HC2 is a nucleic acid hybridization assay with signal
amplification that combines antibody capture of DNA
and RNA probe hybrids and chemiluminescent signal
detection. The HPV HC2 test is designed to detect 13
carcinogenic HPV types (types 16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, and 68) without distinguishing the
HPV type present. The test was performed according to
the manufacturer’s instructions in the laboratory at the
University of Costa Rica.
With each assay a cut-off RLU (relative light units)
value is calculated as the mean RLU value of three posi-
tive calibrators. Specimens with relative light units/cut-
off (RLU/CO) value < 1.00 were considered negative;
specimens with RLU/CO value ≥1.00 were considered
positive for one or more of the carcinogenic HPV types
detected by the test. Given that the magnitude of the
RLU value above the cutoff of the assay is indicative of
the total amount of high risk HPV type present, the
results of this assay were used as a surrogate for HPV
viral load.
Determination of antibodies against HPV-16/18 L1 VLPs
by ELISA
An enzyme-linked immunosorbent assay (ELISA) was
used for the detection and quantitative determination of
IgG antibodies against HPV-16 or 18 in serum speci-
mens. HPV-16 and HPV-18 antibodies were measured
separately; the assay was performed by GlaxoSmithKline
Biologicals as described previously [15]. Briefly, 96 poly-
styrene well plates (MaxiSorp, Nunc) were coated at ~4°
Celsius with VLP-16 (2.7 μg/mL) or VLP-18 (2.7 μg/ml)
which were produced in a baculovirus expression sys-
tem. After incubation and washing steps, plates were
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Tween 20. Samples were serially diluted in the blocking
solution starting at 1/100 in two-fold increments. Serial
dilutions of samples, standard, and controls were added
to the microtiter plates. After incubation and washing, a
peroxidase-conjugated anti-human polyclonal antibody
was added to each well. Following incubation and wash-
ing the substrate and chromogen were added. The reac-
tion was stopped and the intensity of the yellow color
obtained was measured at 450/620 nm. Antibody levels,
expressed as ELISA units/mL (EU/mL), were calculated
by interpolation of OD values from the standard curve
and by averaging the calculated concentrations obtained
i nad e f i n e dr e g i o no ft h ec u r v e .T h ea s s a yc u t - o f fw a s
defined to be a value above three standard deviations of
the geometric mean titer taken from a group of HPV-
negative individuals. Seropositivity was defined as a titer
greater than or equal to the assay cutoff established as 8
EU/mL for HPV-16 and 7 EU/mL for HPV-18 [16].
Statistical Analysis
Of the 5871 women that at the enrollment visit had a pel-
vic exam, 8.3% (488) were HPV-16 DNA positive, 3.2%
(188) were HPV-18 DNA positive, 0.5% (30) were HPV-16
and 18 positive. We restricted our analysis to the 484
women HPV-16 DNA positive and the 179 women HPV-
18 DNA positive with available ELISA results. Additional
information regarding the seroprevalence and determi-
nants of HPV16/18 seropositivity for the total population
was evaluated in a separate report [17].
Socio-demographic, sexual behavior, contraceptives,
smoking and reproductive history characteristics, and
cytology and HPV HC2 test results were evaluated as
possible determinants of serological response.
For each characteristic, we calculated unadjusted odds
ratios (ORs) for seropositivity and 95% confidence inter-
val (CIs) using unconditional logistic regression. Of par-
ticular interest were variables that could be markers of
timing of HPV infection (time since sexual debut and
time with most recent partner) or of amount/load of
exposure (number of sexual partners, viral load by HC2,
cytologic finding, hormonal contraception, and condom
use). Possible confounding factors were explored and a
final model was built for each characteristic of interest
adjusting for all other variables that changed the crude
OR estimates by 15% or more. The outcome variables
were seropositivity for antibodies against HPV-16 and
seropositivity for antibodies against HPV-18.
We performed a similar set of analyses restricted to
women with single HPV-16 and single HPV-18 infec-
tions by DNA testing. Results were comparable to those
seen overall (data not shown).
From the HC2 test we used the ratio of relative light
unit values to positive control (RLU/CO) as a surrogate
for HPV viral load. Women were classified as having
low or high viral load based on the median RLU/CO
value observed (RLU/CO ≤ 30 were considered low viral
load and RLU/CO > 30 were considered high viral load).
We assessed dose response associations (p-trend) by
treating ordinal variables as continuous assuming a lin-
ear trend in the models. F test for differences in geo-
metric means were calculated using ANOVA. Analyses
were performed using Stata 10.0.
Results
Among women who were HPV-16 DNA positive, sero-
positivity for antibodies against HPV-16 was 63.0%
(305/484); among HPV-18 DNA positive the seropositiv-
ity for antibodies against HPV-18 was 57.5% (103/179).
Determinants of seropositivity among HPV-16 DNA
positive women
As shown in table 1, which presents unadjusted and
adjusted risk estimates, there were no differences in the
detection of anti-HPV16 antibodies by age (p-trend =
0.73). Among the demographic and sexual behavior fac-
tors evaluated, increasing lifetime number of sexual
partner was significantly associated with seropositivity.
After adjustment for time with most recent partner,
women with three or more sexual partners in their life-
time had a 2-fold increase in the detection of anti-
HPV16 antibodies compared to women with one life-
time sexual partner (p-trend = 0.01). Increasing fre-
quency of sexual intercourse was indicative of increasing
seropositivity; however it was not significant after
adjustment for hormonal contraceptives (p-trend =
0.20).
Age at sexual debut, years since first sexual inter-
course and time with most recent partner were not sig-
nificantly associated with detection of anti-HPV16
antibodies, although suggestive effect was observed for
time with most recent partner (OR 1.54; 95% CI 0.92-
2.58 for > 13 months versus < 4 months; p-trend =
0.10). Other factors such as years of education and mar-
ital status were not associated with seropositivity (data
not shown).
Current use of hormonal contraceptives (oral contra-
ceptive pill or injectable) was associated with seroposi-
tivity (Table 2). Women who reported use of oral
contraceptives during the last month had a 1.88-fold
(95% CI 1.14-3.09) increase in the detection of anti-
HPV16 antibodies and current users of injectables had a
3.38-fold (95% CI 1.39-8.23) increase in the detection of
anti-HPV16 antibodies compared to never users of hor-
monal contraceptives. We observed no significant asso-
ciation between condom use and anti-HPV16
antibodies, although there was suggestive evidence for
reduced seropositivity among women who reported use
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(OR 0.66; 95% CI 0.42-1.03). To ensure that the higher
seropositivity among hormonal contraception users was
n o tc o n f o u n d e db yc o n d o mu s e ,w ee v a l u a t e ds e r o p o s i -
tivity and hormonal contraception for all strata of con-
dom use (never, past, and current). We observed that,
current users of hormonal contraceptives were more
likely to be seropositive compared with never users of
hormonal contraceptives in all strata of condom use.
Current users of hormonal contraceptives who reported
never using condoms had an OR of 2.20 (95% CI 0.83-
5.81) and current users of hormonal contraceptives who
Table 1 Determinants of seropositivity among HPV-16 DNA positive women at enrollment; Demographic and sexual
factors
Women characteristics Anti-HPV16 Unadjusted Final model
1
Negative Positive % OR (95% CI) OR (95% CI)
All women 179 305 63.0
Age
18-19 50 84 62.7 1.00 1.00
20-21 58 79 57.7 0.81 (0.50-1.32) 0.74 (0.44-1.25)
22-23 37 71 65.7 1.14 (0.67-1.94) 0.98 (0.51-1.86)
24-25 34 71 67.6 1.24 (0.73-2.13) 1.04 (0.53-2.06)
p trend 0.27 0.73
Age at sexual debut
≥ 18 53 83 61.0 1.00 1.00
17 33 63 65.6 1.22 (0.71-2.10) 1.22 (0.71-2.10)
16 37 60 61.9 1.04 (0.61-1.77) 1.04 (0.61-1.77)
15 34 57 62.6 1.07 (0.62-1.85) 1.07 (0.62-1.85)
< 15 22 42 65.6 1.22 (0.66-2.27) 1.22 (0.66-2.27)
p trend 0.69 0.69
Years since first sexual intercourse
≤ 1 23 27 54.0 1.00 1.00
2-3 45 75 62.5 1.42 (0.73-2.77) 1.28 (0.65-2.55)
4-5 45 74 62.2 1.40 (0.72-2.73) 1.23 (0.62-2.46)
≥ 6 66 129 66.2 1.66 (0.89-3.13) 1.40 (0.72-2.73)
p trend 0.15 0.39
Frequency sexual intercourse, month
≤ 1 46 48 51.1 1.00 1.00
2-3 26 52 66.7 1.92 (1.03-3.57) 1.85 (0.98-3.46)
4-9 59 110 65.1 1.79 (1.07-2.99) 1.55 (0.91-2.65)
≥ 10 45 92 67.1 1.96 (1.14-3.36) 1.57 (0.89-2.77)
p trend 0.03 0.20
Lifetime number of sexual partners
1 49 63 56.3 1.00 1.00
2 58 92 61.3 1.23 (0.75-2.03) 1.48 (0.87-2.50)
≥ 3 72 150 67.6 1.62 (1.02-2.59) 1.96 (1.19-3.25)
p trend 0.04 0.01
Time with most recent partner, months
< 4 52 69 57.0 1.00 1.00
4-13 56 98 63.6 1.32 (0.81-2.15) 1.24 (0.75-2.05)
> 13 71 138 66.0 1.46 (0.92-2.32) 1.54 (0.92-2.58)
p trend 0.11 0.10
NOTE. HPV, human papillomavirus; OR, odds ratio; CI, confidence interval.
1 For each variable considered the final model adjusts for all variables that changed the crude estimate of risk by 15% or more.
Age: was adjusted for years since first sexual intercourse.
Age at sexual debut: was not adjusted for any co-factors since none of the potential confounders evaluated changed the OR estimates by 15% or more.
Years since first sexual intercourse: was adjusted for use of hormonal contraceptives.
Frequency sexual intercourse, month: was adjusted for use of hormonal contraceptives.
Lifetime number of sexual partners: was adjusted for time with most recent partner.
Time with most recent partner: was adjusted for lifetime number of sexual partners and use of hormonal contraceptives.
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Page 4 of 10Table 2 Determinants of seropositivity among HPV-16 DNA positive women at enrollment; Contraceptive, pregnancy,
smoking status factors
Women characteristics Anti-HPV16 Unadjusted Final model
1
Negative Positive % OR (95% CI) OR (95% CI)
All women 179 305 63.0
Use of hormonal contraceptives
Never 42 45 51.7 1.00 1.00
In the past 49 70 58.8 1.33 (0.76-2.33) 1.33 (0.76-2.33)
Current oral contraceptives 80 161 66.8 1.88 (1.14-3.09) 1.88 (1.14-3.09)
Current injectable 8 29 78.4 3.38 (1.39-8.23) 3.38 (1.39-8.23)
Use of condom
Never 58 108 65.1 1.00 1.00
In the past 74 143 65.9 1.04 (0.68-1.59) 1.12 (0.72-1.73)
Current (last month) 47 54 53.5 0.62 (0.37-1.02) 0.79 (0.46-1.37)
Frequency of condom use
Never or rarely 67 128 65.6 1.00 1.00
Sometimes 30 47 61.0 0.82 (0.48-1.41) 0.91 (0.52-1.59)
Most of the time 32 52 61.9 0.85 (0.50-1.45) 1.04 (0.60-1.81)
Always 46 78 62.9 0.89 (0.56-1.42) 1.01 (0.62-1.65)
Use of condom last sexual intercourse
No 109 226 67.5 1.00 1.00
Yes 70 79 53.0 0.54 (0.37-0.81) 0.66 (0.42-1.03)
Number of pregnancies
0 81 109 57.4 1.00 1.00
1 63 125 66.5 1.47 (0.97-2.24) 1.47 (0.97-2.24)
2 24 43 64.2 1.33 (0.75-2.37) 1.33 (0.75-2.37)
≥ 3 11 28 71.8 1.89 (0.89-4.02) 1.89 (0.89-4.02)
p trend 0.06 0.06
Smoking Status
Never smoked for ≥ 6 months 140 231 62.3 1.00 1.00
Former smoker 15 24 61.5 0.97 (0.49-1.91) 0.97 (0.49-1.91)
Current 24 50 67.6 1.26 (0.74-2.15) 1.26 (0.74-2.15)
Cytology-Hybrid capture, viral load
2
Normal/Low viral load 89 102 53.4 1.00 1.00
LSIL/Low viral load 7 17 70.8 2.12 (0.84-5.34) 2.12 (0.84-5.34)
HSIL/Low viral load 5 16 76.2 2.79 (0.98-7.93) 2.79 (0.98-7.93)
Normal/High viral load 24 61 71.8 2.22 (1.28-3.85) 2.22 (1.28-3.85)
LSIL/High viral load 31 58 65.2 1.63 (0.97-2.75) 1.63 (0.97-2.75)
HSIL/High viral load 15 43 75.1 2.50 (1.30-4.81) 2.50 (1.30-4.81)
NOTE. HPV, human papillomavirus; OR, odds ratio; CI, confidence interval; LSIL, low grade squamous intraepithelial lesion; HSIL, high grade squamous
intraepithelial lesion.
1 For each variable considered the final model adjusts for all variables that changed the crude estimate of risk by 15% or more.
Use of hormonal contraceptives: was not adjusted for any co-factors since none of the potential confounders evaluated changed the OR estimates by 15% or
more.
Use of condom: was adjusted for use of hormonal contraceptives.
Frequency of condom use: was adjusted for use of hormonal contraceptives.
Use of condom last sexual intercourse: was adjusted for use of hormonal contraceptives.
Number of pregnancies, smoking status and cytology-hybrid capture, viral load: were not adjusted for any co-factors since none of the potential confounders
evaluated changed the OR estimates by 15% or more.
2 Low viral load defined as hybrid capture rlu/co ≤ 30; High viral load defined as hybrid capture rlu/co > 30.
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CI 0.65-5.51) relative to condom users who did not use
hormonal contraception.
Number of pregnancies and smoking were not signifi-
cantly associated with anti-HPV16 seropositivity (Table
2), although there was a tendency for seropositivity to
increase with increasing number of pregnancies (OR
1.89; 95% CI 0.89-4.02 for ≥ 3 pregnancies compared to
none; p-trend = 0.06).
Cytology and HC2 viral load measures were signifi-
cantly associated with anti-HPV16 seropositivity (Table
2). Compared to women with a normal cytology and
low viral load, those with evidence of SIL (squamous
intraepithelial lesion) and/or high viral load had a 1.63
to 2.79 fold increase in the detection of anti-HPV16
antibodies.
Since previous studies have suggested that HPV is
responsive to hormonal factors and that hormone levels
modulate HPV viral expression [18,19], we examined
whether the association between hormonal contraceptive
use and anti-HPV16 seropositivity might be explained
by elevated viral load among hormonal contraceptive
users. Table 3 shows the analysis that compared the
geometric mean (GM) for HC2 viral load levels by hor-
monal contraceptive status. We found no evidence that
current hormonal contraceptives users had higher viral
loads than never users (p = 0.66).
Among women with antibodies against HPV16 we cal-
culated the GM for anti-HPV16 levels for each category
of all the variables evaluated and we did not find signifi-
cant differences in serological levels, except for cytology-
HC2 viral load (p = 0.003). Antibody levels were lowest
among women with normal cytology and low viral load
(GM = 50.0); intermediate among women with either
abnormal cytology or high viral load (GM = 71.5); and
highest among women with both an abnormal cytology
and high viral load (women LSIL/high viral load, GM =
121.1; women HSIL/high viral load, GM = 97.7).
Determinants of seropositivity among HPV-18 DNA
positive women
Analyses that parallel those reported above for HPV-16
were performed to evaluate possible determinants of
anti-HPV18 seropositivity among HPV-18 DNA positive
women. Results are summarized in Tables 4 and 5.
Women who reported having sexual intercourse 2-3
t i m e sam o n t hw e r el e s sl i k e l yt ob es e r o p o s i t i v e( c o m -
pared to women having intercourse less than twice a
month); however this finding may be spurious since few
women fell into this category. Compared to never users
of hormonal contraceptives, current users of oral con-
traceptives but not injectables had increased detection
of anti-HPV18 antibodies (OR 2.47, 95% CI 1.08-5.65).
Also, when we evaluated antibody levels among
anti-HPV-18 seropositive women by strata of hormonal
contraceptives, we found that current users of oral con-
traceptives had significantly higher levels of anti-HPV18
(GM = 49.0 for never users, 30.4 for users in the past,
73.2 for current oral contraceptives users, 36.4 for
current injectable users; p = 0.04).
Discussion
We assessed the prevalence and determinants of serolo-
gical response to HPV-16 and HPV-18 infections in a
group of 646 women 18-25 years of age with concomi-
t a n td e t e c t i o no fH P V - 1 6a n d / o rH P V - 1 8a tt h ec e r v i x .
One strength of this analysis is that unlike previous stu-
dies that evaluated determinants of anti-HPV seroposi-
tivity irrespective of cervical HPV infection status
[5-7,9,10,20,21], our analysis was restricted to women
with detectable cervical HPV infection and enabled us
to focus on factors associated with seropositivity given
prevalent HPV infection, also our study included a large
population of young women infected with HPV-16/18,
this group is of particular interest since the majority of
HPV infections are acquired shortly after sexual debut.
The main finding is the observation that factors asso-
ciated with sustained HPV exposure (elevated HPV viral
load or cytological evidence of HPV infection), were posi-
tively associated with anti-HPV16 seropositivity. We also
observed that lifetime number of sexual partners and
possibly frequency of sexual intercourse were associated
with anti-HPV16 seropositivity. To the extent that these
factors reflects increased amount of viral exposure
among infected women, this finding might also corrobo-
rate the association between viral load and seropositivity.
Table 3 Geometric mean for viral load (Hybrid capture, rlu/co values) stratified by use of hormonal contraceptives;
NOTE. rlu/co, relative light units/cutoff
Women characteristics Geometric mean of Hybrid capture rlu/co values p
1
Use of hormonal contraceptives
Never 40.0
In the past 25.8
Current oral contraceptives 30.1
Current injectable 25.9 0.66
1 F test for differences in mean log transformed hybrid capture rlu/co values.
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rent hormonal contraceptive use (oral or injectable con-
traceptives) and anti-HPV16 seropositivity. The effect of
current oral contraceptive use on seropositivity was also
observed for anti-HPV18 antibodies. We initially
hypothesized that this finding could reflect increased
viral load among hormonal contraceptive users given
that previous studies suggested that HPV contains hor-
monal responsive elements and that hormonal exposure
may increase viral replication[18]. However, we saw no
evidence that HC2 viral load was higher among current
users of hormonal contraceptives, suggesting that
Table 4 Determinants of seropositivity among HPV-18 DNA positive women at enrollment; Demographic and sexual
factors
Women characteristics Anti-HPV18 Unadjusted Final model
1
Negative Positive % OR (95% CI) OR (95% CI)
All women 76 103 57.5
Age
18-19 17 27 61.4 1.00 1.00
20-21 25 31 55.4 0.78 (0.35-1.74) 0.83 (0.36-1.91)
22-23 21 24 53.3 0.72 (0.31-1.67) 0.85 (0.30-2.40)
24-25 13 21 61.8 1.02 (0.41-2.55) 1.23 (0.39-3.85)
p trend 0.92 0.73
Age at sexual debut
≥ 18 24 21 46.7 1.00 1.00
17 13 26 66.7 2.29 (0.94-5.55) 2.29 (0.94-5.55)
16 12 21 63.6 2.00 (0.80-5.02) 2.00 (0.80-5.02)
15 17 14 45.2 0.94 (0.38-2.36) 0.94 (0.38-2.36)
< 15 10 21 67.7 2.40 (0.92-6.23) 2.40 (0.92-6.23)
p trend 0.36 0.36
Years since first sexual intercourse
≤ 1 9 11 55.0 1.00 1.00
2-3 18 30 62.5 1.36 (0.47-3.92) 1.25 (0.40-3.93)
4-5 18 23 56.1 1.05 (0.36-3.06) 0.87 (0.28-2.75)
≥ 6 31 39 55.7 1.03 (0.38-2.80) 0.77 (0.25-2.41)
p trend 0.70 0.32
Frequency sexual intercourse, month
≤ 1 17 21 55.3 1.00 1.00
2-3 18 7 28.0 0.31 (0.11-0.93) 0.25 (0.08-0.78)
4-9 24 35 59.3 1.18 (0.52-2.69) 0.97 (0.39-2.39)
≥ 10 16 39 70.9 1.97 (0.83-4.68) 1.47 (0.57-3.81)
p trend 0.03 0.13
Lifetime number of sexual partners
1 20 28 58.3 1.00 1.00
2 18 22 55.0 0.87 (0.37-2.04) 0.89 (0.37-2.15)
≥ 3 38 53 58.2 1.00 (0.49-2.02) 1.02 (0.48-2.17)
p trend 0.96 0.91
Time with most recent partner, months
< 4 18 24 57.1 1.00 1.00
4-13 26 34 56.7 0.98 (0.44-2.17) 0.81 (0.35-1.91)
> 13 32 45 58.4 1.05 (0.49-2.26) 0.84 (0.35-2.04)
p trend 0.87 0.74
NOTE. HPV, human papillomavirus; OR, odds ratio; CI, confidence interval.
1 For each variable considered the final model adjusts for all variables that changed the crude estimate of risk by 15% or more.
Age: was adjusted for years since first sexual intercourse.
Age at sexual debut: was not adjusted for any co-factors since none of the potential confounders evaluated changed the OR estimates by 15% or more.
Years since first sexual intercourse: was adjusted for use of hormonal contraceptives.
Frequency sexual intercourse, month: was adjusted for use of hormonal contraceptives.
Lifetime number of sexual partners: was adjusted for time with most recent partner.
Time with most recent partner: was adjusted for lifetime number of sexual partners and use of hormonal contraceptives.
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Page 7 of 10alternative explanations are needed to explain the asso-
ciation we observed between current hormonal contra-
ceptive use and anti-HPV seropositivity. One
explanation could be that hormonal factors impact the
immune response directly, and thus help regulate anti-
body production in response to HPV infection [22,23].
Therefore, we did observe suggestive, but not statisti-
cally significant, evidence of increasing anti-HPV16 and
anti-HPV18 seropositivity with increasing numbers of
pregnancies.
The main limitation of our study is its cross-sectional
nature. Since HPV DNA infection and anti-HPV
Table 5 Determinants of seropositivity among HPV-18 DNA positive women; Contraceptive, pregnancy, smoking
status factors
Women characteristics Anti-HPV18 Unadjusted Final model
1
Negative Positive % OR (95% CI) OR (95% CI)
All women 76 103 57.5
Use of hormonal contraceptives
Never 17 14 45.2 1.00 1.00
In the past 19 18 48.7 1.15 (0.44-3.00) 1.15 (0.44-3.00)
Current oral contraceptives 31 63 67.0 2.47 (1.08-5.65) 2.47 (1.08-5.65)
Current injectable 9 8 47.1 1.08 (0.33-3.53) 1.08 (0.33-3.53)
Use of condom
Never 27 41 60.3 1.00 1.00
In the past 33 40 54.8 0.80 (0.41-1.56) 0.87 (0.43-1.74)
Current (last month) 16 22 57.9 0.91 (0.40-2.03) 1.19 (0.51-2.80)
Frequency of condom use
Never or rarely 31 50 61.7 1.00 1.00
Sometimes 10 13 56.5 0.81 (0.32-2.06) 0.80 (0.31-2.11)
Most of the time 15 18 54.6 0.74 (0.33-1.69) 0.93 (0.40-2.17)
Always 19 22 53.7 0.72 (0.34-1.53) 0.80 (0.37-1.76)
Use of condom last sexual intercourse
No 54 75 58.1 1.00 1.00
Yes 22 28 56.0 0.92 (0.47-1.77) 1.23 (0.60-2.56)
Number of pregnancies
0 38 44 53.7 1.00 1.00
1 25 39 60.9 1.35 (0.69-2.62) 1.35 (0.69-2.62)
2 11 13 54.2 1.02 (0.41-2.54) 1.02 (0.41-2.54)
≥ 3 2 7 77.8 3.02 (0.59-15.43) 3.02 (0.59-15.43)
p trend 0.29 0.29
Smoking Status
Never smoked for ≥ 6 months 56 75 57.3 1.00 1.00
Former smoker 3 8 72.7 1.99 (0.51-7.85) 1.99 (0.51-7.85)
Current 17 20 54.1 0.88 (0.42-1.83) 0.88 (0.42-1.83)
Cytology-Hybrid capture, viral load
2
Normal/Low viral load 34 45 57.0 1.00 1.00
LSIL-HSIL/Low viral load 4 8 66.7 1.51 (0.42-5.44) 1.51 (0.42-5.44)
Normal/High viral load 12 11 47.8 0.69 (0.27-1.76) 0.69 (0.27-1.76)
LSIL-HSIL/High viral load 24 36 60.0 1.13 (0.57-2.24) 1.13 (0.57-2.24)
NOTE. OR, odds ratio; CI, confidence interval; LSIL, low grade squamous intraepithelial lesion; HSIL, high grade squamous intraepithelial lesion; HPV, human
papillomavirus.
1 For each variable considered the final model adjusts for all variables that changed the crude estimate of risk by 15% or more.
Use of hormonal contraceptives: was not adjusted for any co-factors since none of the potential confounders evaluated changed the OR estimates by 15% or
more.
Use of condom: was adjusted for use of hormonal contraceptives.
Frequency of condom use: was adjusted for use of hormonal contraceptives.
Use of condom last sexual intercourse: was adjusted for use of hormonal contraceptives.
Number of pregnancies, smoking status and cytology-hybrid capture, viral load: were not adjusted for any co-factors since none of the potential confounders
evaluated changed the OR estimates by 15% or more.
2 Low viral load defined as hybrid capture RLU/CO ≤ 30; High viral load defined as hybrid capture RLU/CO > 30.
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Page 8 of 10antibodies were assessed at the same timepoint, we can-
not determine the amount of time each woman had
been infected with HPV-16 and/or HPV-18 at the time
of DNA and serum sample collection. Studies that have
evaluated time between HPV infection and seroconver-
sion have suggested that, on average, antibody serocon-
version occurs 8-12 months after infection, although
these studies did not sample frequently enough [1,2].
We attempted to account for time since infection by
evaluating sexual behavior variables that we believe are
correlates of time since exposure/infection, such as time
since sexual debut (under the assumption that HPV
infection is common and that exposure/infection typi-
cally occurs proximal to sexual debut) and time with
most recent partner (under the assumption that new
exposures/infections are likely to occur at the start of a
new relationship). While our results did suggest that ser-
opositivity was associated with longer time with the most
recent partner the effect was not statistically significant.
Overall, detection of anti-HPV16 and anti-HPV18
antibodies was observed among 63.0% and 57.5% of
women infected with HPV-16 or HPV-18, respectively;
this seropositivity is consistent with that reported by
other investigators that about half of HPV-16 or HPV-
18 DNA positive women are seropositive [7,10,24].
Despite similar rates of anti-HPV16 and anti-HPV18
seropositivity, our findings for determinants of anti-
HPV18 seropositivity were less clear. The only signifi-
cant predictor of anti-HPV18 seropositivity among
HPV-18 infected women was current oral contraceptive
use. Possible explanations include differences in the per-
formance of the ELISA assays designed to measure anti-
bodies against HPV-16 and HPV-18, lower power for
the HPV-18 analysis since the number of HPV-18
infected women (n=179) was smaller than that of HPV-
16 infected women (n=484), or true biological differ-
ences resultant from differences in patterns/location of
infections caused by these two viruses. The later state-
ment is supported by reports that HPV-18 infections are
often under-represented in precancers, and that they are
preferentially associated with the development of cervi-
cal adenocarcinomas that often arise deep in the endo-
cervical canal [25,26].
Conclusions
Our evaluation of the prevalence and determinants of
anti-HPV16 and anti-HPV18 seropositivity among
women with concurrent cervical infection with HPV-16
and/or HPV-18 shows that over half of HPV-16/18
infected women had detectable levels of antibodies to
the HPV type with which they were infected. Factors
associated with sustained HPV exposure were predictive
of seropositivity (including cytology and viral load mea-
sures) as was current hormonal contraceptive use,
suggesting a possible effect of hormones on immune
responses to HPV. Findings were clearer for HPV-16
than for HPV-18, suggesting the need for additional stu-
dies to understand whether these differences are biologi-
cally driven or resultant from study design or assay
performance. Longitudinal studies that evaluate inci-
dently detected HPV infections and follow these infec-
tions to determine whether seroconversion occurs and
their determinants are needed.
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